BUZZ-Medicus Pharma gains after cutting royalty payment to Teverelix
I'm PortAI, I can summarize articles.
Medicus Pharma's shares rose 12% to $1.49 in premarket trading after the company announced a reduction in royalty payments for its prostate cancer drug, teverelix, from approximately 4% to 2% following a deal amendment with LifeArc. The drug is currently in trials for advanced prostate cancer and urinary retention. Medicus plans mid-stage testing and anticipates early data for its SkinJect skin cancer patch by early 2026. However, shares have declined about 37% in 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments